HOME >> MEDICINE >> NEWS
Light-weight heparin has heavy-weight results in heart attack treatment

DALLAS, Heart attack patients treated with the blood-thinner enoxaparin a low molecular weight heparin plus a clot dissolver were significantly less likely to die or have repeat heart attacks within 30 days compared to patients who received unfractionated heparin (UFH), according to a Rapid Track article in todays Circulation: Journal of the American Heart Association.

Patients in the study had what are known as ST-segment elevation myocardial infarctions, which are the most severe type of heart attack. We have very encouraging data but the evidence is not yet sufficient to say that enoxaparin should be standard treatment for severe heart attacks, says Elliott Antman, M.D., associate professor of medicine at Harvard Medical School and director of the coronary care unit of Brigham and Womens Hospital in Boston. However, the data suggest we should pursue a larger clinical trial.

Enoxaparin previously has been shown to be superior to unfractionated heparin (another blood thinner) for patients with milder heart attacks (non-ST segment elevation). It can be given as a simple injection, rather than the continuous infusion required with UFH, and it does not require frequent testing of the patients blood clotting status.

The researchers report their findings from the ENTIRE-TIMI 23 study. This international study involved 483 patients who presented with severe heart attacks at hospitals in the United States and Europe. Participants were randomly assigned either standard reperfusion with a full dose of the clot-dissolving drug tenecteplase (TNK) or combination therapy with abciximab and a half dose of TNK and either unfractionated heparin (UFH) or enoxaparin. Abciximab is a drug that helps keep blood platelets from sticking together to form clots.

The study was designed to evaluate enoxaparin as adjunctive treatment with various forms of reperfusion therapies (TNK, abciximab). To evaluate reperfusion (blood flow) researchers used the TIMI
'"/>

Contact: Carole Bullock
carole.bullock@heart.org
214-706-1279
American Heart Association
4-Mar-2002


Page: 1 2

Related medicine news :

1. The protective effects of heparin in preventing miscarriages in lupus patients
2. Newer formulation of heparin improves outcomes for suspected heart attack patients
3. New studies show mixed results on epilepsy drugs and birth defects
4. Study of obese diabetics explains why low-carb diets produce fast results
5. Sharing clinical trial results with participants may be beneficial
6. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
7. Similar results found in both older and younger patients undergoing weight-loss surgery
8. OHSU researcher says FDA could broaden access to results of clinical drug trials
9. Kinder, gentler procedure gives superior results for stem cell transplants
10. Good results with only one egg in in-vitro fertilization
11. Holiday feasting could sabotage liposuction results

Post Your Comments:
(Date:2/27/2015)... On February 24 2015, Harper’s Bazaar Magazine posted an ... details the development of RT001, a form of topical botulinum ... trials. For those afraid of needles, the idea of a ... if the drug ultimately gets FDA approval it will be ... , “As the article notes, the size of the ...
(Date:2/27/2015)... 27, 2015 Adding to its ... pharmaceuticals, Benedict Advertising & Marketing has added Sedation ... The company’s patented NITROUSEAL® N20 closed mask and ... of sedation. , Sedation Systems, http://www.sedationsystems.com ... a new level, though it focuses primarily on ...
(Date:2/27/2015)... NY (PRWEB) February 27, 2015 The winter ... mold growth and expansion. When mold grows, it can be ... be sure to avoid the consequences of mold growth with ... Long Island, is offering tips on the best ways to ... wet season, which makes perfect conditions for mold to thrive. ...
(Date:2/27/2015)... Vancouver, BC (PRWEB) February 27, 2015 ... exciting overnight deals for couples who wanted to spend ... with the opportunity to get a jump on Valentine’s ... meal and stay in one of their luxurious rooms. ... on February 13, inviting guests for a mouthwatering 3 ...
(Date:2/27/2015)... Florida Hospital North Pinellas is being ... Gold Plus hospital. In order to receive the award, ... to all Get With The Guidelines - Stroke Quality ... and achieved 75-percent or higher compliance with six of ... These are reporting initiatives to measure quality of care. ...
Breaking Medicine News(10 mins):Health News:Is Topical Botox the Next Big Thing? 2Health News:Benedict Advertising & Marketing Signs Sedation Systems 2Health News:Enviro-Test Offers Tips for Winter Mold Prevention 2Health News:Victorian Hotel Celebrated Valentine’s Day in 2015 With Unique Overnight Deal 2Health News:Florida Hospital North Pinellas Receives Get With The Guidelines - Stroke Gold Plus Quality Achievement Award 2
(Date:2/27/2015)... Feb. 27, 2015  PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the fourth quarter and full ... was a transformative year for PTC. We are now ... developing RNA-targeted therapies in the rare disease space," stated ... Inc. "We are proud to bring the first treatment ...
(Date:2/27/2015)... 2015  Bionik Laboratories Corp. (OTC:DWTPD), a ... it acquired Bionik Laboratories, Inc., a Toronto ... to qualified accredited investors of units consisting of its ... approximately $6.2 million. Shares of the Company,s common stock ... under the symbol "DWTPD" until FINRA,s approval of the ...
(Date:2/26/2015)... -- RnRMarketResearch.com adds Corneal Ulcers - ... its store. This report p provides an overview ... The report "Corneal Ulcers - Pipeline Review, H2 2014" provides ... Ulcers. Corneal Ulcers are primarily result of the ... & fungal infections. The symptoms of the corneal ...
Breaking Medicine Technology:PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5
Cached News: